IL134776A0 - A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST - Google Patents

A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST

Info

Publication number
IL134776A0
IL134776A0 IL13477698A IL13477698A IL134776A0 IL 134776 A0 IL134776 A0 IL 134776A0 IL 13477698 A IL13477698 A IL 13477698A IL 13477698 A IL13477698 A IL 13477698A IL 134776 A0 IL134776 A0 IL 134776A0
Authority
IL
Israel
Prior art keywords
combination
reuptake inhibitor
partial agonist
ht1b antagonist
ht1b
Prior art date
Application number
IL13477698A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL134776A0 publication Critical patent/IL134776A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Replacement Of Web Rolls (AREA)
  • Winding, Rewinding, Material Storage Devices (AREA)
IL13477698A 1997-09-18 1998-09-09 A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST IL134776A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703375A SE9703375D0 (sv) 1997-09-18 1997-09-18 A new combination
PCT/SE1998/001601 WO1999013877A1 (en) 1997-09-18 1998-09-09 A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST

Publications (1)

Publication Number Publication Date
IL134776A0 true IL134776A0 (en) 2001-04-30

Family

ID=20408295

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13477698A IL134776A0 (en) 1997-09-18 1998-09-09 A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST

Country Status (29)

Country Link
US (1) US6159971A (cg-RX-API-DMAC10.html)
EP (1) EP1014985B1 (cg-RX-API-DMAC10.html)
JP (1) JP2001516718A (cg-RX-API-DMAC10.html)
KR (1) KR20010024076A (cg-RX-API-DMAC10.html)
CN (1) CN1195519C (cg-RX-API-DMAC10.html)
AR (1) AR015448A1 (cg-RX-API-DMAC10.html)
AT (1) ATE240733T1 (cg-RX-API-DMAC10.html)
AU (1) AU752722B2 (cg-RX-API-DMAC10.html)
BR (1) BR9812088A (cg-RX-API-DMAC10.html)
CA (1) CA2302382A1 (cg-RX-API-DMAC10.html)
DE (1) DE69814882T2 (cg-RX-API-DMAC10.html)
DK (1) DK1014985T3 (cg-RX-API-DMAC10.html)
EE (1) EE04141B1 (cg-RX-API-DMAC10.html)
ES (1) ES2200370T3 (cg-RX-API-DMAC10.html)
HU (1) HUP0200602A3 (cg-RX-API-DMAC10.html)
IL (1) IL134776A0 (cg-RX-API-DMAC10.html)
IS (1) IS5406A (cg-RX-API-DMAC10.html)
MY (1) MY116280A (cg-RX-API-DMAC10.html)
NO (1) NO20001399L (cg-RX-API-DMAC10.html)
NZ (1) NZ503171A (cg-RX-API-DMAC10.html)
PL (1) PL339371A1 (cg-RX-API-DMAC10.html)
PT (1) PT1014985E (cg-RX-API-DMAC10.html)
RU (1) RU2214824C2 (cg-RX-API-DMAC10.html)
SE (1) SE9703375D0 (cg-RX-API-DMAC10.html)
SK (1) SK2852000A3 (cg-RX-API-DMAC10.html)
TR (1) TR200000727T2 (cg-RX-API-DMAC10.html)
TW (1) TW589183B (cg-RX-API-DMAC10.html)
WO (1) WO1999013877A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA987817B (cg-RX-API-DMAC10.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
WO2002066454A1 (fr) * 2001-02-21 2002-08-29 Sankyo Company, Limited Derives de chromene
CA2445843A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram
US7504395B2 (en) * 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
SE0203778D0 (sv) * 2002-12-09 2002-12-09 Astrazeneca Ab A new oral immediated release dosage form
AR047553A1 (es) 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
KR100511288B1 (ko) * 2003-11-14 2005-08-31 엘지전자 주식회사 4대의 압축기를 구비한 공기조화기의 실외기
US20060217394A1 (en) * 2005-02-23 2006-09-28 Silvan S. Tomkins Institute, Inc. Treatment of anhedonia
CA2617546C (en) 2005-08-03 2014-07-15 Boehringer Ingelheim International Gmbh Use of flibanserin in the treatment of obesity
FR2890862B1 (fr) * 2005-09-19 2008-01-25 Sanofi Aventis Sa Association d'agoniste aux recepteurs beta 3 et d'inhibiteur de la recapture de monoamnies, compostion pharmaceutique la contenant et son utilisation en therapeutique.
WO2007048803A1 (en) 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
RU2477634C2 (ru) * 2006-06-16 2013-03-20 Теракос, Инк. Лечение психологических состояний с применением антагонистов m1-мускариновых рецепторов
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
WO2008000760A1 (en) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
CA2660476C (en) 2006-08-14 2015-11-17 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
WO2008022932A2 (en) 2006-08-25 2008-02-28 Boehringer Ingelheim International Gmbh Controlled release system and method for manufacturing the same
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
ES2162792T3 (es) * 1991-09-18 2002-01-16 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d.
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
SE9703374D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination

Also Published As

Publication number Publication date
EP1014985A1 (en) 2000-07-05
CN1278729A (zh) 2001-01-03
HUP0200602A3 (en) 2003-04-28
ZA987817B (en) 1999-03-18
NO20001399D0 (no) 2000-03-17
HUP0200602A2 (hu) 2002-07-29
RU2214824C2 (ru) 2003-10-27
IS5406A (is) 2000-03-15
JP2001516718A (ja) 2001-10-02
DE69814882T2 (de) 2004-05-19
TW589183B (en) 2004-06-01
CA2302382A1 (en) 1999-03-25
DK1014985T3 (da) 2003-09-15
MY116280A (en) 2003-12-31
HK1032739A1 (en) 2001-08-03
EE04141B1 (et) 2003-10-15
US6159971A (en) 2000-12-12
PT1014985E (pt) 2003-10-31
BR9812088A (pt) 2000-09-26
AU752722B2 (en) 2002-09-26
DE69814882D1 (de) 2003-06-26
ES2200370T3 (es) 2004-03-01
TR200000727T2 (tr) 2000-09-21
NO20001399L (no) 2000-05-10
EE200000141A (et) 2001-02-15
SE9703375D0 (sv) 1997-09-18
KR20010024076A (ko) 2001-03-26
AU9193098A (en) 1999-04-05
PL339371A1 (en) 2000-12-18
AR015448A1 (es) 2001-05-02
CN1195519C (zh) 2005-04-06
EP1014985B1 (en) 2003-05-21
NZ503171A (en) 2002-02-01
ATE240733T1 (de) 2003-06-15
WO1999013877A1 (en) 1999-03-25
SK2852000A3 (en) 2000-09-12

Similar Documents

Publication Publication Date Title
ZA987817B (en) A combination of a 5-HT reuptake inhibitor and a h5-HT1b antagonist or partial agonist
HUP0203586A3 (en) The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist
HUP0103408A3 (en) Methods of using and compositions comprising dopamine reuptake inhibitors
IL134775A0 (en) A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST
IL127214A0 (en) Inhibition of serotonin reuptake
PL337781A1 (en) Antagonists and reverse antagonists of glucogene
IL117988A0 (en) A new combination of an inhibitor and an antagonist
CY2242B1 (en) Benzonitriles and -fluorides as 5-ht agonists and antagonists
IL151518A0 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase
PL330195A1 (en) Antagonist of dopamine d4 receptor
EP1028958A4 (en) ARYLPIPERAZINES ACTING AS SEROTONIN REABSORPTION INHIBITORS AND AS 5-HT1D ALPHA ANTAGONISTS
ZA9710989B (en) Polyprolyl inhibitors of cyclophilin
IL134774A0 (en) A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVE h5-HT1B ANTAGONIST OR PARTIAL AGONIST
SI1014985T1 (en) A combination of a 5-ht reuptake inhibitor and a h5-ht 1b antagonist or partial agonist
SI1237553T1 (sl) Kombinacija inhibitorja ponovnega navzema serotonina in antagonista 5-ht 2c?, inverznega agonista ali delnega agonista
GB9700233D0 (en) Use of glycosidase inhibitors
SI1021183T1 (en) A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVE h5-HT1B ANTAGONIST OR PARTIAL AGONIST
AU3148500A (en) Scale and corrosion inhibitor
HK1032738A (en) A combination of a monoamine oxidase inhibitor and a h5-ht 1 beta antagonist or partial agonist
SI0822813T1 (en) A combination of a 5-ht uptake inhibitor with a selective 5-ht 1a antagonist
GB9619055D0 (en) Corrosion inhibitor
GB9600736D0 (en) Corrosion and scale inhibitors
SI1263745T1 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase
GB9626443D0 (en) Inhibitor blends
GB9803416D0 (en) Inhibitors